Pricing Strategy, NRDL listing tactics for 2 key assets of a pharma MNC for China

Objective

To finalize the revenue & profit optimizing pricing strategy and access tactics for 2 rare
disease assets of a pharma MNC for China, with potential for >$150mn sales over 5yrs
Approach

Undertook pricing deep dive and analog analysis for NRDL listing, insights derived to guide the pricing strategy & negotiation tactics
Deliverables

Analog (pricing) analysis for NRDL listing, target price for the two assets, negotiation tactics for getting listed
Outcome

Pricing strategy endorsed by global senior management, local organization adopted the approach in the local dossier preparation for NRDL pricing negotiations

Objective